Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
16 sept. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms’ Tumor 1 (WT1), an...
Intellia Therapeutics to Present at September Healthcare Investor Conferences
31 août 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
05 août 2021 07h30 HE
|
Intellia Therapeutics, Inc.
Established proof of concept for the Company’s modular in vivo delivery platform with first-ever clinical data from systemically administered CRISPR genome editing candidate in humansInterim Phase 1...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates
29 juil. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock
02 juil. 2021 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
29 juin 2021 21h08 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
28 juin 2021 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
26 juin 2021 11h15 HE
|
Intellia Therapeutics, Inc.
First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean...
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
24 juin 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
04 juin 2021 07h30 HE
|
Intellia Therapeutics, Inc.
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidateLate-breaking abstract selected for oral presentation on...